Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal Atrial Fibrillation Patients

Atrial Fibrillation Clinical Trial

Official title:

Prevalence of Use of Anticoagulant, and Associated Factors of Anticoagulant Refusal in Non-valvular Atrial Fibrillation Patients---- A Study in Hong Kong General Out-patient Clinic

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04062071
• Other study ID #: version1 last update 30/7/2019
• Status: Not yet recruiting
• Start date: August 23, 2019
• Est. completion date: March 23, 2020

Study information

• Verified date: August 2019
• Source: Prince of Wales Hospital, Shatin, Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Atrial fibrillation is a clinically significant cardiac arrhythmia that increases the risk of stroke by 3 to 4 times. Oral anticoagulation has been shown to mitigate stroke risk by two-thirds among patients with AF and is widely recommended in optimizing AF management.Direct oral anticoagulants have also been demonstrated to be superior to warfarin with respect to the risk of fatal bleeding and stroke prevention.

However, the previous study finding highlighted a great gap between current guidelines and the clinical management of AF .Nonetheless, the decision for anticoagulant use is not straightforward.It is worth to investigate the updated prevalence of anticoagulant use, the reasons for not receiving anticoagulant, and the factors independently associated with anticoagulant refusal in patients with non-valvular atrial fibrillation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: March 23, 2020
• Est. primary completion date: March 23, 2020
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• diagnosis as atrial fibrillation

• aged ?18 years

• able to given consent

Exclusion Criteria:

• Unable/unwillingness to sign informed consent to study

• mechanical heart valve

• moderate-to-severe mitral stenosis

• Transient atrial fibrillation from reversible cause (e.g., during respiratory tract infection or bronchospasm)

• pregnancy

• hospitalization within 1 month prior to inclusion in the study.

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Other:
• no intervention
no intervention

Locations

Country	Name	City	State
Hong Kong	LIAO, Jiawei	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Prince of Wales Hospital, Shatin, Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The prevalence of anticoagulant use in non-valvular atrial fibrillation patients	calculate the prevalence of anticoagulant use in non-valvular atrial fibrillation patients	August 2019 to March 2020
Secondary	the rate of the refusal of anticoagulant use	calculate the rate of refusal of anticoagulant use in the eligible non-valvular atrial fibrillation patients	August 2019 to March 2020